Dr. Samaniego is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 832-729-0759Fax+1 713-792-7543- Is this information wrong?
Summary
- Dr. Felipe Samaniego is an oncologist in Houston, TX and is affiliated with University of Texas M.D. Anderson Cancer Center. He received his medical degree from Harvard Medical School and has been in practice for 34 years. He speaks multiple languages, including Spanish. Dr. Samaniego specializes in hematologic oncology and is experienced in hematopoietic stem cell transplantation, follicular lymphoma, health outcomes research, general medical oncology, and gout suppressants.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1986 - 1990
University of ColoradoResidency, Internal Medicine, 1983 - 1986
Harvard Medical SchoolClass of 1983
Certifications & Licensure
AZ State Medical License 2022 - 2026
NM State Medical License 2023 - 2026
TN State Medical License 2022 - 2025
WA State Medical License 2022 - 2025
GA State Medical License 2022 - 2024
LA State Medical License 2022 - 2024
TX State Medical License 2011 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- Waun Ki Hong Award for Excellence in Team Science The University of Texas MD Anderson Cancer Center, 2016
- ASH Annual Meeting, Moderator American Society of Hematology, 2016
- Robert Wood Johnson Foundation Fellow 1989-2016
- Join now to see all
Clinical Trials
- Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas Start of enrollment: 2015 Jul 01
- Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) Start of enrollment: 2016 May 23
- Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Start of enrollment: 2016 May 25
- Join now to see all
Publications & Presentations
PubMed
- Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 s...Max J Gordon, Lei Feng, Paolo Strati, Hun Ju Lee, Fredrick B Hagemeister, Jason R Westin, Felipe Samaniego, Mario L Marques-Piubelli, Francisco Vega Vazquez, Edwin R P...> ;Cancer. 2024 Mar 15
- 15 citationsSmart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.Jason Westin, R Eric Davis, Lei Feng, Fredrick Hagemeister, Raphael Steiner, Hun Ju Lee, Luis Fayad, Loretta Nastoupil, Sairah Ahmed, Alma Rodriguez, Michelle Fanale, ...> ;Journal of Clinical Oncology. 2023 Feb 1
- 19 citationsFollicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression.Guangchun Han, Qing Deng, Mario L Marques-Piubelli, Enyu Dai, Minghao Dang, Man Chun John Ma, Xubin Li, Haopeng Yang, Jared Henderson, Olga Kudryashova, Mark Meerson, ...> ;Blood Cancer Discovery. 2022 Sep 6
- Join now to see all
Journal Articles
- Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin LymphomaPeter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
- Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational StudyFelipe Samaniego, Boris Blechacz, Ahmed Kaseb, Bruno P Granwehr, Aung Naing, Issam I Raad, Ethan Miller, Harrys A Torres, Nature
- Resolution of lung adenocarcinoma after discontinuation of ibrutinibKhashab T, Loghavi S, Konoplev SN, Samaniego F, BMJ Case Rep, 2016
Abstracts/Posters
- Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin LymphomaHamadani ME, Collins GP, Phil D, Samaniego F, Spira AI, Davis AN, Radford J, Caimi P, Menne TO, Boni J, Cruz H, Feingold J, He SH, Wuerthner J, Horwitz SM, Blood, 12/2018
- Acalabrutinib plus pembrolizumab in relapsed/refractory diffuse large b‐cell lymphoma: a phase 1/2 studyWitzig TE, Maddocks K, Vos S, Lyons R, Edenfield W, Sharman J, Yimer H, Wei H, Chan E, Patel P, Simone C, Gandhi M, Vaughn J, Kolibaba K, Cheson B, Samaniego F, Hematological Oncology, 6/2019
- Preliminary results of astx660, a novel non‐peptidomimetic ciap1/2 and xiap antagonist, in relapsed/refractory peripheral t‐cell lymphoma and cutaneous t cell lymphomaSamaniego F, Hollebecque A, Foss F, Lister J, Mita M, Wagner-Johnston N, Dyer M, You B, Prica A, Hernandez-Llizaliturri F, Ferraldeschi R, Chan D, Zhang J, Mehta A, Hematological Oncology, 6/2019
- Join now to see all
Lectures
- Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of Patients2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R) in Previously Untreated Follicular...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid LeukemiaDecember 13th, 2021
Early Experience with Remdesivir to Treat Severe COVID-19 PublishedApril 10th, 2020
Best of MD Anderson 2019: Top Cancer Insights from Our ExpertsDecember 17th, 2019- Join now to see all
Grant Support
- Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell TransplantBristol-Myers Squibb2017–2021
- A Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin LymphomaMerck Sharp & Dohme Corp2016–2020
- Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and LymphomasAstex Pharmaceuticals2017–2019
- A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with B-cell MalignanciesAcerta Pharma LLC2016–2019
- Study of a PI3K inhibitor in ibrutinib resistant diffuse large B cell lymphomaKarus Therapeutics2016–2018
- Cancer Cell Overexpression of Death Receptor ModularNIH/NCI2012–2014
- Preservation of liver function through modulation of Fas-binding proteinsNIH2011–2014
- Specialized Program of Research ExcellenceNIH2011–2013
- Gastrointestinal Research Regulation of Proliferation and Apoptosis in Hepatocellular CarcinomaHogan2011–2013
- Gastrointestinal Research Regulation of Proliferation and Apoptosis in Hepatocellular CarcinomaG.S. Hogan2011–2013
- PMLRARa and PML directly regulate Fas-mediated apoptosis in vivoNIH2011–2013
- Targeting of Fas Inhibitor Proteins in Hematopoietic CancersLeukemia and Lymphoma Society2008–2011
- Correlative studies in treatment of CLL with MilatuzimabLadies Leukemia League2009–2010
- Targeting CD74 in the therapy of lymphomaCancer Fighters Houston2009–2010
- Fas Inhibitors in Hematopoietic CancersUTMDACC Center for Targeted Therapy (CTT)2008–2010
- Analysis of Fas-inhibitor regulation of apoptosis in normal and malignant tissuesU. T. M.D. Anderson Cancer Center2008–2010
- K1 from HHV-8 Modulates Fas: A Model for Inducing Cell SuicideLeukemia and Lymphoma Society2005–2010
- Human herpesvirus 8 K1 as a model for regulation of apoptosisHogg Foundation2007
- HHV-8 K1 Lymphoid Hyperplasia and Suppressed ApoptosisMD Anderson Cancer Center2006–2007
- HIV-1 Tat Activates PKB/Akt and Enhances Cell SurvivalNIH/ NCI2004–2006
- Lymphocytes Expressing Human Herpes Virus 8 K1 Show NF-kB ActivationConcern Foundation2002–2004
- Tat's Promotion of Kaposi's SarcomaNIH/ NCI1999–2004
Committees
- Member, Multidisciplinary Research Advisory Committee 2013 - 2015
- Member, Department of Scientific Publications Advisory Board 2012 - 2015
- Member, IRG Translational Research Grant Review Committee 2011 - 2015
Other Languages
- Spanish
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
